Genentech said that the phase III IMpower133 study met its co-primary endpoints of overall survival and progression-free survival at its first interim analysis.
When The Cancer Letter founder Jerry Boyd carried the first print run of his little eight page oncology newsletter into an NCAB meeting in 1973, he certainly could not have predicted that, half a century later, his experiment would branch out into this thing called “podcasts.”
